Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33

Inclusion Criteria:

main inclusion:

1. Evidence of a personally signed informed consent document;
2. Male and/or female subjects above the ages of 18 years;
3. Locally advanced or metastatic solid tumor patients who have failed or relapsed on current standard of care for Phase 1a;
4. Subject may provide Tumor tissue section(at least 8 pieces) if they agree;
5. ECOG performance score 0-1;
6. Life expectancy ≥ 12 weeks;
7. At least 1 measurable target lesion on the baseline scan as per RECIST 1.1

Exclusion Criteria:

main criteria:

1. prior received anti-tumor treatment, including anticancer drugs for the treatment within 28 days of first dose of study treatment;
2. Prior or concomitant other malignant tumor;